+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation



A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation



RadioTherapy and Oncology 113(1): 84-88



To compare the risks of radiogenic second cancers and cardiac mortality in 17 pediatric medulloblastoma patients treated with passively scattered proton or field-in-field photon craniospinal irradiation (CSI). Standard of care photon or proton CSI treatment plans were created for all 17 patients in a commercial treatment planning system (TPS) (Eclipse version 8.9; Varian Medical Systems, Palo Alto, CA) and prescription dose was 23.4 or 23.4 Gy (RBE) to the age specific target volume at 1.8 Gy/fraction. The therapeutic doses from proton and photon CSI plans were estimated from TPS. Stray radiation doses were determined from Monte Carlo simulations for proton CSI and from measurements and TPS for photon CSI. The Biological Effects of Ionization Radiation VII report and a linear model based on childhood cancer survivor data were used for risk predictions of second cancer and cardiac mortality, respectively. The ratios of lifetime attributable risk (RLARs) (proton/photon) ranged from 0.10 to 0.22 for second cancer incidence and ranged from 0.20 to 0.53 for second cancer mortality, respectively. The ratio of relative risk (RRR) (proton/photon) of cardiac mortality ranged from 0.12 to 0.24. The RLARs of both cancer incidence and mortality decreased with patient's age at exposure (e), while the RRRs of cardiac mortality increased with e. Girls had a significantly higher RLAR of cancer mortality than boys. Passively scattered proton CSI provides superior predicted outcomes by conferring lower predicted risks of second cancer and cardiac mortality than field-in-field photon CSI for all medulloblastoma patients in a large clinically representative sample in the United States, but the magnitude of superiority depends strongly on the patients' anatomical development status.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051108737

Download citation: RISBibTeXText

PMID: 25128084

DOI: 10.1016/j.radonc.2014.07.003


Related references

Comparison of risk of radiogenic second cancer following photon and proton craniospinal irradiation for a pediatric medulloblastoma patient. Physics in Medicine and Biology 58(4): 807-823, 2013

Predicted risks of radiogenic cardiac toxicity in two pediatric patients undergoing photon or proton radiotherapy. Radiation Oncology 8(1): 184, 2013

Hypothyroidism after craniospinal irradiation with proton or photon therapy in patients with medulloblastoma. Pediatric Hematology and Oncology 35(4): 257-267, 2018

SU-E-T-257: Risk of Radiogenic Second Cancer after Photon and Proton Craniospinal Irradiation. Medical Physics 39(6part13): 3762-3962, 2012

Effects of vertebral-body-sparing proton craniospinal irradiation on the spine of young pediatric patients with medulloblastoma. Advances in Radiation Oncology 2(2): 220-227, 2017

A review of dosimetric and toxicity modeling of proton versus photon craniospinal irradiation for pediatrics medulloblastoma. Acta Oncologica 56(8): 1031-1042, 2017

Reduced acute toxicity for adults with medulloblastoma treated with proton beam craniospinal irradiation. Strahlentherapie und Onkologie 190(1): 111-112, 2014

Comparison of Endocrine Dysfunction and Dosimetry in Pediatric Patients Treated With Proton Versus Photon Radiation Therapy for Medulloblastoma. International Journal of Radiation Oncology*Biology*Physics 93(3): S32-S33, 2015

Acute toxicity and treatment interruption related to electron and photon craniospinal irradiation in pediatric patients treated at the University of Texas M. D. Anderson Cancer Center. International Journal of Radiation Oncology Biology Physics 52(4): 1008-1016, 2002

Predicted risks of second malignant neoplasm incidence and mortality due to secondary neutrons in a girl and boy receiving proton craniospinal irradiation. Physics in Medicine and Biology 55(23): 7067-7080, 2010

Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Medical & Pediatric Oncology 28(5): 348-354, 1997

A Comparative Planning Analysis and Integral Dose of Volumetric Modulated Arc Therapy, Helical Tomotherapy, and Three-dimensional Conformal Craniospinal Irradiation for Pediatric Medulloblastoma. Journal of Medical Imaging and Radiation Sciences 46(2): 134-140, 2015

Comparison of therapeutic dosimetric data from passively scattered proton and photon craniospinal irradiations for medulloblastoma. Radiation Oncology 7: 116, 2012

Meta-analysis of the incidence and patterns of second neoplasms after photon craniospinal irradiation in children with medulloblastoma. Pediatric Blood and Cancer 65(8): E27095, 2018

Growth Outcomes of Pediatric Patients Receiving Proton Craniospinal Irradiation. International Journal of Radiation Oncology*biology*physics 99(2): E566-E567, 2017